OBJECTIVE： To investigate the clinical efficacy of alprostadil combined with edaravone in the treatment of unstable angina pectoris （UAP）， and their effects on serum oxidative stress indexes， the levels of MMP-2 and MMP-9. METHODS： Besides conventional treatment， control group was treated with Alprostadil injection 2 ml added into 0.9％ Sodium chloride injection （NS） 100 ml， ivgtt， qd； while observation group was additionally treated with Edaravone injection 15 ml added into NS 100 ml， ivgtt， qd. Treatment courses of 2 groups lasted for 2 weeks. The frequency and duration of UAP attack， serum levels of MDA， SOD， TAC， MMP-2 and MMP-9 levels were observed 2 groups； the occurrence of ADR was also observed. RESULTS： There was no statistical significance in frequency of angina pectoris attack， duration，MDA，SOD，TAC，MMP-2 and MMP-9 between 2 groups before treatment （P＞0.05）. After treatment， the total effective rate of observation group （94.3％） was significantly higher than that of control group （81.4％）. The frequency of angina pectoris attack and the level of MDA， were significantly reduced， and the duration of angina pectoris was significantly shortened SOD and TAC increased significantly； the change of observation group was more significant than that of control group with statistical significance （P＜0.05）. ADR was mild in 2 groups； there was no statistical significance in the incidence of ADR （P＞0.05）. CONCLUSIONS： Alprostadil combined with edaravone is significantly effective for UAP， reduces the frequency of angina， shortens the duration of angina pectoris， alleviates oxidative stress and reduces serum levels of MMP-2 and MMP-9 with good safety.